These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2906475

  • 1. Evolution of olsalazine.
    Truelove SC.
    Scand J Gastroenterol Suppl; 1988; 148():3-6. PubMed ID: 2906475
    [Abstract] [Full Text] [Related]

  • 2. Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis.
    Jewell DP, Ireland A.
    Scand J Gastroenterol Suppl; 1988; 148():45-7. PubMed ID: 2906477
    [Abstract] [Full Text] [Related]

  • 3. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL, Campbell BJ, Dwarakanath AD, Yaqoob M, Stevenson A, Morris AI, Rhodes JM.
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [Abstract] [Full Text] [Related]

  • 4. Pharmacology of olsalazine.
    Campbell DE, Berglindh T.
    Scand J Gastroenterol Suppl; 1988 Dec; 148():7-12. PubMed ID: 3067340
    [Abstract] [Full Text] [Related]

  • 5. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.
    Ewe K, Eckardt V, Kanzler G.
    Scand J Gastroenterol Suppl; 1988 Dec; 148():70-5. PubMed ID: 2906479
    [Abstract] [Full Text] [Related]

  • 6. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.
    Rao SS, Dundas SA, Holdsworth CD, Cann PA, Palmer KR, Corbett CL.
    Gut; 1989 May; 30(5):675-9. PubMed ID: 2567266
    [Abstract] [Full Text] [Related]

  • 7. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis.
    Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB.
    Scand J Gastroenterol Suppl; 1988 May; 148():40-4. PubMed ID: 2906476
    [Abstract] [Full Text] [Related]

  • 8. An experiment to determine the active therapeutic moiety of sulphasalazine.
    Azad Khan AK, Piris J, Truelove SC.
    Lancet; 1977 Oct 29; 2(8044):892-5. PubMed ID: 72239
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
    Rao SS, Cann PA, Holdsworth CD.
    Scand J Gastroenterol; 1987 Apr 29; 22(3):332-6. PubMed ID: 2884724
    [Abstract] [Full Text] [Related]

  • 11. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.
    Ireland A, Mason CH, Jewell DP.
    Gut; 1988 Jun 29; 29(6):835-7. PubMed ID: 2898422
    [Abstract] [Full Text] [Related]

  • 12. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N, Weir DG, Kelleher D.
    Ir J Med Sci; 1999 Jun 29; 168(4):228-32. PubMed ID: 10624358
    [Abstract] [Full Text] [Related]

  • 13. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.
    Meyers S, Sachar DB, Present DH, Janowitz HD.
    Scand J Gastroenterol Suppl; 1988 Jun 29; 148():29-37. PubMed ID: 2906474
    [Abstract] [Full Text] [Related]

  • 14. Colonic prostaglandin E2 levels and olsalazine metabolism in relapsing ulcerative colitis: implications for controlled trials in the long term.
    Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J.
    Scand J Gastroenterol Suppl; 1988 Jun 29; 148():76-80. PubMed ID: 3067341
    [Abstract] [Full Text] [Related]

  • 15. Sulphasalazine: a review of 40 years' experience.
    Watkinson G.
    Drugs; 1986 Jun 29; 32 Suppl 1():1-11. PubMed ID: 2877847
    [Abstract] [Full Text] [Related]

  • 16. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.
    Kiilerich S, Ladefoged K, Rannem T, Ranløv PJ.
    Gut; 1992 Feb 29; 33(2):252-5. PubMed ID: 1347280
    [Abstract] [Full Text] [Related]

  • 17. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.
    Kruis W, Judmaier G, Kayasseh L, Stolte M, Theuer D, Scheurlen C, Hentschel E, Kratochvil P.
    Eur J Gastroenterol Hepatol; 1995 May 29; 7(5):391-6. PubMed ID: 7614099
    [Abstract] [Full Text] [Related]

  • 18. Olsalazine in patients intolerant of sulphasalazine.
    Ireland A, Jewell DP.
    Scand J Gastroenterol; 1987 Nov 29; 22(9):1038-40. PubMed ID: 2892247
    [Abstract] [Full Text] [Related]

  • 19. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
    Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, Weir DG.
    Lancet; 1992 May 23; 339(8804):1279-81. PubMed ID: 1349676
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.